United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,400
Employees1,400
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,400
Employees1,400

UTHR Key Statistics

Market cap
21.91B
Market cap21.91B
Price-Earnings ratio
18.44
Price-Earnings ratio18.44
Dividend yield
Dividend yield
Average volume
484.95K
Average volume484.95K
High today
$515.00
High today$515.00
Low today
$490.74
Low today$490.74
Open price
$509.20
Open price$509.20
Volume
293.31K
Volume293.31K
52 Week high
$537.19
52 Week high$537.19
52 Week low
$266.98
52 Week low$266.98

Stock Snapshot

The current United Therapeutics(UTHR) stock price is $499.97, with a market capitalization of 21.91B. The stock trades at a price-to-earnings (P/E) ratio of 18.44.

As of 2026-03-03, United Therapeutics(UTHR) stock has fluctuated between $490.74 and $515.00. The current price stands at $499.97, placing the stock +1.9% above today's low and -2.9% off the high.

United Therapeutics(UTHR) shares are trading with a volume of 293.31K, against a daily average of 484.95K.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $537.19 and a 52-week low of $266.98.

In the last year, United Therapeutics(UTHR) shares hit a 52-week high of $537.19 and a 52-week low of $266.98.

UTHR News

Benzinga 1d
United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening

United Therapeutics Inc. (NASDAQ:UTHR) stock gained on Monday after it shared positive news regarding its drug ralinepag, which achieved a significant milestone...

United Therapeutics' Trial Shows 55% Drop in Lung Disease Worsening
TipRanks 1d
United Therapeutics’ Ralinepag Trial Success Boosts PAH Outlook

The latest announcement is out from United Therapeutics ( (UTHR) ). On March 2, 2026, United Therapeutics reported that its pivotal phase 3 ADVANCE OUTCOMES tr...

TipRanks 1d
United Therapeutics says phase 3 ADVANCE OUTCOMES study met its primary endpoint

United Therapeutics (UTHR) announced that its long-term pivotal phase 3 ADVANCE OUTCOMES study met its primary endpoint, with ralinepag reducing the risk of a c...

Analyst ratings

71%

of 14 ratings
Buy
71.4%
Hold
28.6%
Sell
0%

More UTHR News

Simply Wall St 2d
A Look At MannKind Valuation After New United Therapeutics Inhaler Raises Royalty Concerns

MannKind (MNKD) is back in focus after partner United Therapeutics introduced a soft mist inhaler designed to compete with Tyvaso DPI, raising fresh questions a...

A Look At MannKind Valuation After New United Therapeutics Inhaler Raises Royalty Concerns
Simply Wall St 3d
United Therapeutics Tresmi Launch And Record Revenue Shape Valuation Debate

United Therapeutics unveiled its new Tresmi soft mist inhaler platform, designed to improve patient experience in pulmonary hypertension treatment. The company...

United Therapeutics Tresmi Launch And Record Revenue Shape Valuation Debate
Benzinga 5d
These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings

United Therapeutics Corp (NASDAQ:UTHR) reported better-than-expected earnings for the fourth quarter on Wednesday. The company posted quarterly earnings of $7....

These Analysts Increase Their Forecasts On United Therapeutics After Upbeat Q4 Earnings
TipRanks 6d
United Therapeutics announces ‘category killer product’ Tresmi

On its earnings conference call earlier, United Therapeutics (UTHR) announced a “category killer product” called Tresmi, a “revolutionary proprietary drug devic...

Nasdaq 6d
United Therapeutics Corp Q4 Profit Rises

(RTTNews) - United Therapeutics Corp (UTHR) released earnings for its fourth quarter that Increased, from last year The company's earnings came in at $364.3 mi...

United Therapeutics Corp Q4 Profit Rises
Simply Wall St 7d
Assessing United Therapeutics Valuation After Mixed Short And Long Term Share Performance

Advertisement United Therapeutics stock: recent performance snapshot With no single headline event driving the move, United Therapeutics (UTHR) has drawn atte...

Assessing United Therapeutics Valuation After Mixed Short And Long Term Share Performance

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.